LBPH (Longboard Pharmaceuticals) Total Assets : $297.01 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Longboard Pharmaceuticals Total Assets?

Longboard Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2024 was $297.01 Mil.

During the past 12 months, Longboard Pharmaceuticals's average Total Assets Growth Rate was 200.50% per year. During the past 3 years, the average Total Assets Growth Rate was 33.60% per year.

During the past 4 years, Longboard Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 33.60%. The lowest was 33.60%. And the median was 33.60%.

Total Assets is connected with ROA %. Longboard Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2024 was -32.19%. Total Assets is also linked to Revenue through Asset Turnover. Longboard Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2024 was 0.00.

Longboard Pharmaceuticals Total Assets Historical Data

The historical data trend for Longboard Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longboard Pharmaceuticals Total Assets Chart

Longboard Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Assets

56.24

108.95

70.62

50.70

Longboard Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Assets	Get a 7-Day Free Trial														58.86	50.70	327.67	312.91	297.01

Longboard Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Longboard Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	40.923	+	9.774
	=	50.70

Longboard Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2024 )	+	Total Liabilities (Q: Sep. 2024 )
	=	275.186	+	21.819
	=	297.01

Longboard Pharmaceuticals (NAS:LBPH) Total Assets Explanation

Total Assets is connected with ROA %.

Longboard Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %	=	Net Income (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	-98.16	/	( (312.905	+	297.005)	/ 2 )
	=	-98.16	/	304.955
	=	-32.19 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Longboard Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2024 is

	Asset Turnover
=	Revenue (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
=	0	/	( (312.905	+	297.005)	/ 2 )
=	0	/	304.955
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Longboard Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Longboard Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Longboard Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longboard Pharmaceuticals Inc (NAS:LBPH) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

4275 Executive Square, Suite 950, La Jolla, CA, USA, 92037

Website

https://www.longboardpharma.com

Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.

Executives

Randall Kaye	officer: CMO	11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Arena Pharmaceuticals Inc	10 percent owner	6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jane Tiller	director	C/O LONGBOARD PHARMACEUTICALS, INC., 4275 EXECUTIVE DRIVE, SUITE 950, LA JOLLA CA 92037
Brandi Roberts	officer: Chief Financial Officer	12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Phillip M Schneider	director	GEN-PROBE INCORPORATED, 10210 GENETIC CENTER DRIVE, SAN DIEGO CA 92121
Vincent Aurentz	director	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Kevin Robert Lind	director, officer: President and CEO	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Paul J Sekhri	director	C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Casey Lynch	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Le Goff Corinne	director	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Philip Perera	officer: Chief Medical Officer	C/O LONGBOARD PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121